Published in Nat Chem Biol on December 14, 2015
Interview with Thomas Lundbäck, PhD. Assay Drug Dev Technol (2016) 0.75
Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient. Front Oncol (2017) 0.75
Chemical probes: The many genes of drug mechanism. Nat Chem Biol (2016) 0.75
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 40.30
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Discovery and saturation analysis of cancer genes across 21 tumour types. Nature (2014) 11.68
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc (2007) 10.71
Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A (2001) 7.51
How were new medicines discovered? Nat Rev Drug Discov (2011) 7.00
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol (2007) 6.16
DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science (2005) 5.20
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol (2014) 4.65
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science (2013) 4.39
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (2013) 4.20
Analysis of the human endogenous coregulator complexome. Cell (2011) 2.97
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol (2013) 2.64
Neural computing in cancer drug development: predicting mechanism of action. Science (1992) 2.38
An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell (2013) 2.30
New approaches to molecular cancer therapeutics. Nat Chem Biol (2006) 2.28
Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev (2011) 1.93
Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol (2009) 1.91
Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov (2014) 1.86
Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure (2004) 1.84
FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res (1998) 1.78
Methods for quantification of in vivo changes in protein ubiquitination following proteasome and deubiquitinase inhibition. Mol Cell Proteomics (2012) 1.58
Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat Rev Genet (2004) 1.53
HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro. Life Sci (1982) 1.31
Phenotypic screening in cancer drug discovery - past, present and future. Nat Rev Drug Discov (2014) 1.29
Sharing and Specificity of Co-expression Networks across 35 Human Tissues. PLoS Comput Biol (2015) 1.27
Crystal structure of phosphodiesterase 4D and inhibitor complex(1). FEBS Lett (2002) 1.14
Phosphodiesterase 3A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser428. Biochem J (2005) 1.04
Targeting the undruggable proteome: the small molecules of my dreams. Chem Biol (2010) 1.03
Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart. Circ Res (2012) 0.95
Minireview: dynamic structures of nuclear hormone receptors: new promises and challenges. Mol Endocrinol (2013) 0.94
Chemical genomics: a systematic approach in biological research and drug discovery. Curr Issues Mol Biol (2002) 0.86
Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease. Neurotherapeutics (2015) 0.84
The 47kDa Akt substrate associates with phosphodiesterase 3B and regulates its level in adipocytes. Biochem Biophys Res Commun (2006) 0.84
Positive inotropic effect of levosimendan is correlated to its stereoselective Ca2+-sensitizing effect but not to stereoselective phosphodiesterase inhibition. Basic Clin Pharmacol Toxicol (2006) 0.84
Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model. J Biomol Screen (2006) 0.84
Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors. Eur J Pharmacol (1994) 0.84
PDE3 inhibition in dilated cardiomyopathy. Curr Opin Pharmacol (2011) 0.84
Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Semin Thromb Hemost (1997) 0.83
Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis. Mol Pharmacol (2002) 0.83
Cyclic nucleotide phosphodiesterase 3 signaling complexes. Horm Metab Res (2012) 0.82
Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. Br J Pharmacol (2005) 0.80
Role of protein phosphatases in malignant transformation. Princess Takamatsu Symp (1989) 0.79
Cilostazol for intermittent claudication. Cochrane Database Syst Rev (2014) 0.79
Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms. J Thromb Haemost (2015) 0.77
Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol (2015) 1.20
High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat Biotechnol (2016) 0.84
Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. Elife (2017) 0.84
Chemical perturbation of an intrinsically disordered region of TFIID distinguishes two modes of transcription initiation. Elife (2015) 0.83
A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nat Commun (2016) 0.80
Characterizing genomic alterations in cancer by complementary functional associations. Nat Biotechnol (2016) 0.77
Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun (2016) 0.76
PIK3CA mutant tumors depend on oxoglutarate dehydrogenase. Proc Natl Acad Sci U S A (2017) 0.75
Divergent Synthesis and Real-Time Biological Annotation of Optically Active Tetrahydrocyclopenta[c]pyranone Derivatives. Org Lett (2016) 0.75
Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet (2017) 0.75
Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action. Nat Commun (2020) 0.75
Synthesis of a bicyclic azetidine with in vivo antimalarial activity enabled by stereospecific, directed C(sp(3))-H arylation. J Am Chem Soc (2017) 0.75
Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells. Nat Chem Biol (2017) 0.75
Complementary information derived from CRISPR Cas9 mediated gene deletion and suppression. Nat Commun (2017) 0.75
Stereospecific Palladium-Catalyzed C-H Arylation of Pyroglutamic Acid Derivatives at the C3 Position Enabled by 8-Aminoquinoline as a Directing Group. Org Lett (2017) 0.75